Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss ...

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss ...

Results from the Phase III REAL8 basket study found that once-weekly Sogroya was effective in children with growth disorders, including those born small for gestational age, with Noonan syndrome, or ...

Novo lumps sales of Norditropin and Sogroya together into its rare endocrine disorders category, which grew sales 31% in 2024 to roughly 5 billion Danish kroner ($745 million).

Novo Nordisk reports phase 3 data showing weekly Sogroya matched or outperformed daily hormone therapy in multiple pediatric growth disorders.

The REAL8 trial showed that after 52 weeks, once-weekly Sogroya® (somapacitan) had similar clinical outcomes and safety profile to once-daily Norditropin® (somatropin) in children born small for ...

Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin (somatropin) in children’s growth disorders in a Phase III trial. The Danish ...

Genotropin Cart, Norditropin SimpleXx and Saizen Click.easy dominated the growth hormone market by volume, accounting for 30%, 24% and 17.5%, respectively, of prescribed growth hormone in the second ...

Skytrofa is a prescription drug used to treat growth hormone deficiency in children. Learn about the common, mild, and serious side effects it can cause.

Somatropin Medication Information Learn everything you need to know about Somatropin-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information ...

Learn about uses, side effects, and more of Skytrofa (lonapegsomatropin-tcgd), a prescription injection that treats growth hormone deficiency in certain children.